An investigator-sponsored, open-label, single dose, safety and tolerability study clinical study of a Durasert implant to treat severe OA of the knee.

Trial Profile

An investigator-sponsored, open-label, single dose, safety and tolerability study clinical study of a Durasert implant to treat severe OA of the knee.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs Dexamethasone (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.
    • 14 Dec 2017 According to pSivida media release, Dr. Mark P. Figgie, Chief of the Surgical Arthritis Service at Hospital for Special Surgery is the principal investigator of the study.
    • 14 Dec 2017 Results published in the pSivida Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top